Purple Biotech Ltd. (IL:PPBT)
TASE:PPBT
Want to see IL:PPBT full AI Analyst Report?
Top Page
Purple Biotech
(TASE:PPBT)
Select Model
Select Model
Rating:43Neutral
Price Target:
0.97
▼(-19.58% Downside)
Action:Reiterated
Date:05/21/26
The score is primarily constrained by weak financial performance: minimal revenue, large ongoing losses, and continued negative operating/free cash flow, with a shrinking equity base raising financing risk. Technicals are also soft (below longer-term moving averages with slightly negative MACD and sub-50 RSI). Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Low leverage / financial flexibility
Very low debt gives the company structural financial flexibility at a clinical stage. With limited interest burden, management can prioritize R&D spend and negotiate partner deals without heavy refinancing pressure, supporting sustained operations while pursuing trials.
Negative Factors
Large recurring losses
Sustained, sizable operating losses with essentially no product revenue indicate the company remains pre-commercial and dependent on milestones or financing. Over months this depletes capital, constrains strategic choices, and raises execution risk until clinical or partnership milestones materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / financial flexibility
Very low debt gives the company structural financial flexibility at a clinical stage. With limited interest burden, management can prioritize R&D spend and negotiate partner deals without heavy refinancing pressure, supporting sustained operations while pursuing trials.
Read all positive factors
Purple Biotech (PPBT) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪18.58M
Dividend YieldN/A
Average Volume (3M)8.90M
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue GrowthN/A
EPS Growth-17.14%
CountryIL
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding1,858,479,500
10 Day Avg. Volume1,387,469
30 Day Avg. Volume8,902,795
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Purple Biotech Business Overview & Revenue Model
Company Description
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that...
How the Company Makes Money
Purple Biotech primarily generates revenue through collaboration and licensing arrangements related to its drug candidates, which can include upfront payments, reimbursement for research and development services, milestone payments tied to clinica...
Purple Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 195.80K | 0.00 | 0.00 |
| Gross Profit | -177.19K | 0.00 | -62.00K | -196.00 | -120.00 | -55.00 |
| EBITDA | -7.44M | -29.72M | -7.05M | -19.88M | -21.49M | -17.52M |
| Net Income | -25.94M | -28.79M | -7.24M | -19.88K | -21.67M | -18.38M |
Balance Sheet | ||||||
| Total Assets | 14.56M | 17.58M | 37.04M | 44.30M | 54.62M | 70.20M |
| Cash, Cash Equivalents and Short-Term Investments | 6.49M | 9.58M | 8.52M | 15.41M | 32.11M | 47.20M |
| Total Debt | 185.77K | 244.05K | 183.00K | 351.00K | 515.00K | 749.00K |
| Total Liabilities | 4.80M | 7.91M | 4.13M | 10.01M | 7.52M | 5.09M |
| Stockholders Equity | 9.82M | 9.72M | 32.86M | 34.21M | 46.91M | 64.83M |
Cash Flow | ||||||
| Free Cash Flow | -4.62M | -5.95M | -14.37M | -19.93M | -16.96M | -15.19M |
| Operating Cash Flow | -6.64M | -5.95M | -14.37M | -19.93M | -16.73M | -15.07M |
| Investing Cash Flow | 248.71K | 482.78K | 509.00K | 13.88M | 19.91M | 13.41M |
| Financing Cash Flow | 6.11M | 6.88M | 6.77M | 5.45M | 1.11M | 1.51M |
Purple Biotech Technical Analysis
Negative
1.20
Price Trends
1.00
Positive
1.05
Negative
1.53
Negative
Market Momentum
>-0.01
Negative
40.92
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:PPBT, the sentiment is Negative. The current price of 1.2 is above the 20-day moving average (MA) of 1.00, above the 50-day MA of 1.00, and below the 200-day MA of 1.53, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.92 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:PPBT.
Purple Biotech Risk Analysis
Purple Biotech disclosed 77 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Purple Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₪33.94M | -2.32 | ― | ― | -96.19% | 97.86% | |
46 Neutral | ₪20.76M | ― | ― | ― | ― | ― | |
45 Neutral | ₪28.72M | -1.31 | ― | ― | -100.00% | -29.02% | |
43 Neutral | ₪18.58M | -17.21 | ― | ― | ― | -17.14% |
* Healthcare Sector Average
IL:PPBT
Purple Biotech
1.00
-3.20
-76.19%
IL:XTLB
Xtl Bio
1.90
-2.30
-54.76%
IL:CBI
Clal Biotech
30.00
-0.70
-2.28%
IL:BLRX
Bioline Rx
1.30
-0.80
-38.10%
IL:CANF
Can Fite Bio
484.50
483.20
37169.23%
IL:BOLT
Biolight
316.30
-206.10
-39.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.